Blocking soluble TNFα sensitizes HER2-positive breast cancer to trastuzumab through MUC4 downregulation and subverts immunosuppression

BRUNI, SOFIA; MAURO, FLORENCIA L; PROIETTI, CECILIA J; CORDO-RUSSO, ROSALIA I; RIVAS, MARTIN A; INURRIGARRO, GLORIA; DUPONT, AGUSTINA; ROCHA, DARIO; FERNÁNDEZ, ELMER A; DEZA, ERNESTO GIL; LOPEZ DELLA VECCHIA, DANIEL; BARCHUK, SABRINA; FIGURELLI, SILVINA; LASSO, DAVID; FRIEDRICH, ADRIÁN D; SANTILLI, MARÍA C; REGGE, MARÍA V; LEBERSZTEIN, GABRIEL; LEVIT, CLAUDIO; ANFUSO, FABIANA; CASTIGLIONE, TERESA; ELIZALDE, PATRICIA V; MERCOGLIANO, MARIA F; SCHILLACI, ROXANA

Journal for ImmunoTherapy of Cancer

BMJ

Año: 2023 vol. 11

Background The success of HER2-positive (HER2+) breast cancer treatment with trastuzumab, an antibody that targets HER2, relies on immune response. We demonstrated that TNFα induces mucin 4 (MUC4) expression, which shields the trastuzumab epitope on the HER2 molecule decreasing its therapeutic effect. Here, we used mouse models and samples from HER2+ breast cancer patients to unravel MUC4 participation in hindering trastuzumab effect by fostering immune evasion.Methods We used a dominant negative TNFα inhibitor (DN) selective for soluble TNFα (sTNFα) together with trastuzumab. Preclinical experiments were performed using two models of conditionally MUC4-silenced tumors to characterize the immune cell infiltration. A cohort of 91 patients treated with trastuzumab was used to correlate tumor MUC4 with tumor-infiltrating lymphocytes.Results In mice bearing de novo trastuzumab-resistant HER2+ breast tumors, neutralizing sTNFα with DN induced MUC4 downregulation. Using the conditionally MUC4-silenced tumor models, the antitumor effect of trastuzumab was reinstated and the addition of TNFα-blocking agents did not further decrease tumor burden. DN administration with trastuzumab modifies the immunosuppressive tumor milieu through M1-like phenotype macrophage polarization and NK cells degranulation. Depletion experiments revealed a cross-talk between macrophages and NK cells necessary for trastuzumab antitumor effect. In addition, tumor cells treated with DN are more susceptible to trastuzumab-dependent cellular phagocytosis. Finally, MUC4 expression in HER2+ breast cancer is associated with immune desert tumors.Conclusions These findings provide rationale to pursue sTNFα blockade combined with trastuzumab or trastuzumab drug conjugates for MUC4+ and HER2+ breast cancer patients to overcome trastuzumab resistance.